Multidisciplinary Approach in the NAFLD/NASH Patient Care Pathway
There is a significant push within the medical community to devise simpler, more cost-efficient ways to assess and monitor NAFLD/NASH patients. In this 5-minute video, Dr. Manuel Romero-Gómez, professor of medicine at the University of Seville, Sevilla, Spain, discusses the need for a multidisciplinary approach in the NAFLD/NASH patient care pathway and how noninvasive tests like the Enhanced Liver Fibrosis (ELF™) Test can help.
The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.
In the U.S., the ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events.